33 British Thoracic Society. Guidelines for the management of asthma. 2011. http://www.brit-thoracic.org.uk/ClinicalInformation/Asthma/AsthmaGuidelines/tabid/83/Default.aspx

34 Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; 4:CD006923. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006923.pub2/abstract

35 Anon. Using beta 2-stimulants in asthma. Drug Ther Bull 1997; 35:1–4.

36 NICE. Omalizumab for severe persistent allergic asthma [TA133]. 2007. https://www.nice.org.uk/guidance/TA133

37 Hensley MJ. Use of inhaled corticosteroids was associated with the development of cataracts. Evid Based Med 1998; 3:24. http://ebm.bmj.com/content/3/1/24.full.pdf+html

38 Anon. Beyond the lungs—a new view of COPD. Lancet 2007; 370:713. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61349-X/abstract

39 Wouters E. COPD: a chronic and overlooked pulmonary disease. Lancet 2007; 370:715–16. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61352-X/abstract

40 Steiner M, Barton RL, Singh SJ, et al. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 2003;58(9):745–51. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746806/

41 Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3:CD001287. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001287.pub2/abstract

42 Soriano JB, Lamprecht B, Ramírez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med 2015; 3(6):443–50. http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00157-5/abstract

43 Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364:1093–103. http://www.nejm.org/doi/full/10.1056/NEJMoa1008378

44 Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus separate components for COPD. Cochrane Database Syst Rev 2007; 4:CD003794. http://www.ncbi.nlm.nih.gov/pubmed/17943798

45 Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149(3 Pt 1):818–24. http://www.atsjournals.org/doi/pdf/10.1164/ajrccm.149.3.7509706

46 Diaz-Reganon Valverde G, Fernández Rico R, Iribarren Sarrías JL, et al. The administration of 20 ppm of inhaled nitric oxide produces a faster response than the inhalation of 5 ppm in adult respiratory distress syndrome. Rev Esp Anesthesiol Reanim 2000; 47(2):57–62

47 Afshari A, Brok J, Møller AM, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev 2010; 7:CD002787. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002787.pub2/abstract

48 Lamontagne F, Briel M, Guyatt GH, et al. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care 2010; 25(3):420–35. http://www.jccjournal.org/article/S0883-9441(09)00234-2/abstract

49 Deal EN, Hollands JM, Schramm GE, et al. Role of corticosteroids in the management of acute respiratory distress syndrome. Clin Ther 2008; 30(5):787–99. http://www.sciencedirect.com/science/article/pii/S0149291808001823

50 Davies C, Gleeson FV, Davies RJ, et al. BTS guidelines for the management of pleural infection. Thorax 2003; 58 Suppl 2:ii18–28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766018/

51 Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378–84. http://www.nejm.org/doi/full/10.1056/NEJM200005113421901

52 NICE. Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome [TA139]. 2008. http://www.nice.org.uk/Guidance/TA139

53 Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357(21):2153–65. http://www.nejm.org/doi/full/10.1056/NEJMra071714

54 Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63(Suppl V):v1–v58. http://thorax.bmj.com/content/63/Suppl_5/v1.long

55 Grönhagen-Riska C. Angiotensin-converting enzyme. I. Activity and correlation with serum lysozyme in sarcoidosis, other chest or lymph node diseases and healthy persons. Scand J Respir Dis 1979; 60(2):83–93

56 Iannuzzi MC, Sah BP. Sarcoidosis. In: Merk Manual. http://www.merckmanuals.com/professional/pulmonary_disorders/sarcoidosis/sarcoidosis.html

57 Evans M, Sharma O, LaBree L, et al. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. Ophthalmology 2007; 114(2):325–33. http://www.aaojournal.org/article/S0161-6420(06)00994-8/abstract

58 Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63:v1–v58 http://thorax.bmj.com/content/63/Suppl_5/v1.long

59 Watanabe N, Tanada S, Sasaki Y. Pulmonary clearance of aerosolized 99mTc-DTPA in sarcoidosis I patients. Q J Nucl Med Mol Imaging 2007; 51(1):82–90. http://www.minervamedica.it/en/journals/nuclear-med-molecular-imaging/issue.php?cod=R39Y9999N00

60 Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63(Suppl V):v1–v58. http://thorax.bmj.com/content/63/Suppl_5/v1.long

61 Fisher M, Nathan SD, Hill C, et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm 2017; 23(3):S17–S24.